<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606863</url>
  </required_header>
  <id_info>
    <org_study_id>ELX-NPP-2016-01</org_study_id>
    <nct_id>NCT03606863</nct_id>
  </id_info>
  <brief_title>Peripheral Parenteral Nutrition vs Conventional Fluid in Colorectal Resection in ERAS</brief_title>
  <official_title>A RANDOMIZED, CONTROLLED, CLINICAL TRIAL TO COMPARE PERIPHERAL PARENTERAL NUTRITION (PeriOlimel N4-E) VERSUS CONVENTIONAL FLUID THERAPY IN ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL IN COLORECTAL CANCER SURGERY.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonio Arroyo Sebastian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess if administration of early nutrition support with Perioperative Peripheral Nutrition
      (PeriOliclimonel) N4-E) in patients undergoing colon cancer resection in an Enhanced Recovery
      After Surgery (ERAS) Protocol improve the results of morbi-mortality and hospitalization
      versus standard intravenous fluid therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is to determine if perioperative nutritional support with PeriOlimel N4-E,
      that reaches nutritional requirements of ERAS protocol for colorectal cancer surgery
      patients, can improve nutritional status so it decreases postoperative complications,
      hospital length of stay and costs, compared to conventional fluid therapy administration
      since patients receive oral nutrition at day 3-5.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>morbi-mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Early Peripheral Parenteral Nutrition in patients undergoing colon cancer resection in an Enhanced Recovery After Surgery Protocol to improve the results of morbi-mortality and hospitalization versus standard intravenous fluid therapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Parenteral Nutrition</condition>
  <condition>Fast-track</condition>
  <arm_group>
    <arm_group_label>Perioperative peripheral parenteral nutrition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perioperative peripheral parenteral nutrition during 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard fluid therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard fluid therap</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perioperative peripheral parenteral nutrition</intervention_name>
    <arm_group_label>Perioperative peripheral parenteral nutrition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  scheduled colorectal cancer surgery

          -  ASA I-IV

        Exclusion Criteria:

          -  Emergency surgery

          -  Distant metastasis

          -  Patient´s refusal to participate

          -  Allergy or hypersensitivity to egg or soy protein

          -  Advanced kidney or hepatic impairment

          -  Severe bleeding disorders

          -  Congenital abnormalities of amino acid metabolism

          -  Hyperlipidemia and severe or difficult to control hyperglycemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Arroyo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación para el fomento de la investigación sanitaria y biomédica de la Comunidad Valenciana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Arroyo, MD</last_name>
    <phone>966 616 000</phone>
    <email>arroyocir@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANTONIO ARROYO, MD</last_name>
      <phone>966 616 000</phone>
      <email>arroyocir@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>July 28, 2018</last_update_submitted>
  <last_update_submitted_qc>July 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</investigator_affiliation>
    <investigator_full_name>Antonio Arroyo Sebastian</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

